These backgrounders provide more in-depth information on various topics related to insulin degludec including:
- Insulin degludec and insulin degludec / insulin aspart backgrounder
- Diabetes backgrounder
- Hypoglycaemia backgrounder
Insulin degludec is an ultra-long-acting basal insulin being developed by Novo Nordisk. Insulin degludec and insulin degludec / insulin aspart have been submitted to regulatory authorities for review but have not yet been approved for use.
APROM ID# 4045. Date of Approval: May 2012